Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Atrial Fibrillation Clinical Trials

A listing of Atrial Fibrillation medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (312) clinical trials

Prospective, multicenter, randomized, active control, clinical trial of the Coherex WaveCrest Left Atrial Appendage (LAA) device compared to the Watchman® LAA device for the reduction in risk of ischemic stroke or systemic embolism in subjects with non-valvular atrial fibrillation who have an appropriate rationale to seek a non-pharmacologic alternative to ...

Phase N/A

Cardiac Resynchronization Therapy (CRT) as a treatment for heart failure has demonstrated benefits in clinical status, reduced heart failure hospitalizations, and improved mortality. However, a persistent rate of non-response and left ventricular lead issues remain, creating an unmet clinical need to provide an alternative for stimulating the left ventricle (LV). ...

Phase N/A

Eligibility Criteria: Once you have decided to participate and have learned of the details of the trial you will be seen and evaluated for the following: To be eligible to participate you will be evaluated for Severity of aortic stenosis. You must meet criteria for heart team agreement of low ...

Phase

Eligibility Criteria: Inclusion Criteria:•Age > or equal to 18 years of age•History of non-paroxysmal form of AF as defined by the HRS/EHRA/ECAS Consensus Statement:◦Persistent AF shall be defined as continuous AF that is sustained beyond seven days. Episodes of AF in which a decision is made to electrically or pharmacologically ...

Phase

Evaluation of the CIRCA Monitoring System in Prevention of Esophageal Lesions Following RFCA

Dr. Gregory Feld, M.D. is conducting a research study to find out more about the short-term effects on the esophagus of left atrial ablation (guided by Circa esophageal temperature monitoring system). The financial supporter of this study is Circa Scientific, LLC. When the investigators perform a radiofrequency catheter ablation (RFCA) ...

Phase N/A

Comparison of High Versus Escalating Shocks in Cardioverting Atrial Fibrillation

The optimal energy selection for biphasic direct current (DC) cardioversion of atrial fibrillation is unknown. The energy delivered should be sufficient to achieve prompt cardioversion but without the risk of inducing any potential injury e.g. skin burns, myocardial stunning or post-cardioversion arrhythmias. The use of an escalating protocol, with a ...

Phase N/A

Clinical Investigation of the VytronUS Ablation System for Treatment of Symptomatic Drug-refractory Paroxysmal Atrial Fibrillation

Patients undergoing elective catheter ablation for symptomatic PAF who are refractory or intolerant to at least one antiarrhythmic drug (Class I-IV) will be screened for enrollment. Patients who meet the study entry criteria and sign the patient informed consent form will be enrolled and treated consistent with the 2012 Heart ...

Phase N/A

Efficacy of Delayed Enhancement MRI-Guided Ablation vs Conventional Catheter Ablation of Atrial Fibrillation

BACKGROUND AND INTRODUCTION: Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting millions of people in the US and around the world. Treating AF continues to be a challenge. Over the last 15 years, catheter based AF ablation procedure has been widely adopted. Approximately 50% of patients treated with ...

Phase N/A

Correlation of the Arrhythmia Mechanism and Substrate to Ablate Persistent Atrial Fibrillation Study

Pulmonary vein isolation catheter ablation for the treatment of persistent AF (PeAF)or longstanding persistent AF is associated with success rates of 40-50% at one year. Experimental models have shown that AF results in progressive structural changes due to electrical atrial remodeling, where AF burden correlates with atrial fibrosis. The optimal ...

Phase N/A

Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation

1.0 Background While atrial fibrillation (AF) is the most common sustained cardiac arrhythmia requiring therapy, it is also associated with increased risk of stroke, heart failure, myocardial infarction, dementia, and death. The number of Americans affected with AF is expected to surge to nearly 16 million by the year 2050. ...

Phase